Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
In 2000/2001, a 7-valent pneumococcal conjugate vaccine (PCV-7) was licensed in Europe. During the following years and based on positive experiences from the USA, more and more European countries recommended routine immunization of infants and of children at an increased risk for invasive pneumococcal disease. Many studies documented the impact on invasive pneumococcal disease, but also on noninvasive pneumococcal disease. This review summarizes current evidence on the population-based impact of infant immunization programs in Europe.
Rose
Markus
M
Children's Hospital, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany. markus.rose@kgu.de
Zielen
Stefan
S
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks / Q000517:prevention & control*; D017277:Drug Approval; D005060:Europe / Q000453:epidemiology; D019317:Evidence-Based Medicine; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D007223:Infant; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D013997:Time Factors; D014481:United States / Q000453:epidemiology; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate